I just deleted this from the drug pipeline cause I thought you had beat me to it but I guess I will repost it.
October 31, 2006 07:00 AM Eastern Time
Opexa Therapeutics to Present at Rodman & Renshaw Eighth Annual Healthcare Conference
Rodman & Renshaw Healthcare Conference 2006
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced that its chief executive officer, David McWilliams, will present at the upcoming Rodman & Renshaw Eighth Annual Healthcare Conference. The presentation is scheduled for 9:55 AM (Eastern Time) on Tuesday, November 7, 2006. The event will be held from November 6-8, 2006 at the New York Palace Hotel in New York.
Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Opexa’s web site www.opexatherapeutics.com
a few minutes prior to start time to download any necessary software.
The conference will feature presentations from more than 290 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com
About Opexa Therapeutics
Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com
Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100